Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly

Acromegaly Clinical Trial Methodology Impact on Reported Biochemical Efficacy Rates of Somatostatin Receptor Ligand Treatments: A Meta-Analysis

(2014) John D. Carmichael et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Acromegaly: An Endocrine Society Clinical Practice Guideline

(2014) Laurence Katznelson et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study

(2014) A. Colao et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Efficacy of the new long-acting formulation of lanreotide (Lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly

(2014) G. Lombardi et al.   JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION

Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naïve to radiation and medical therapy

(2014) E. Ghigo et al.   JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION

Expert consensus document: A consensus on the medical treatment of acromegaly

(2014) Andrea Giustina et al.   Nature Reviews Endocrinology

Failure of Current Laboratory Protocols to Detect Lot-to-Lot Reagent Differences: Findings and Possible Solutions

(2013) A. Algeciras-Schimnich et al.   CLINICAL CHEMISTRY

Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism

(2013) Akira Shimatsu et al.   ENDOCRINE JOURNAL

Effects of Lanreotide Autogel on Growth Hormone, Insulinlike Growth Factor 1, and Tumor Size in Acromegaly: A 1-Year Prospective Multicenter Study

(2013) Roberto Attanasio et al.   Endocrine Practice

American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly-2011 Update

(2013) Laurence Katznelson et al.   Endocrine Practice

A Comprehensive Study of Clinical, Biochemical, Radiological, Vascular, Cardiac, and Sleep Parameters in an Unselected Cohort of Patients With Acromegaly Undergoing Presurgical Somatostatin Receptor Ligand Therapy

(2013) Anand K. Annamalai et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression

(2012) Leandro Kasuki et al.   ENDOCRINE-RELATED CANCER

Novel pathway for somatostatin analogs in patients with acromegaly

(2012) Mônica R. Gadelha et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Consensus Statement on the Standardization and Evaluation of Growth Hormone and Insulin-like Growth Factor Assays

(2011) D. R. Clemmons et al.   CLINICAL CHEMISTRY

Harmonization of growth hormone measurements with different immunoassays by data adjustment

(2011) Anne Müller et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure

(2011) Sven M. Carlsen et al.   CLINICAL ENDOCRINOLOGY

Comparison of primary octreotide-lar and surgical treatment in newly diagnosed patients with acromegaly

(2011) Z. Karaca et al.   CLINICAL ENDOCRINOLOGY

Resistance to Somatostatin Analogs in Acromegaly

(2011) Annamaria Colao et al.   ENDOCRINE REVIEWS

Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly

(2011) Yasemin Tutuncu et al.   Pituitary

Efficacy and Acceptability of Lanreotide Autogel® 120 mg at Different Dose Intervals in Patients with Acromegaly Previously Treated with Octreotide LAR

(2010) J. Schopohl et al.   EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES

The value of an acute octreotide suppression test in predicting response to long-term somatostatin analogue therapy in patients with acromegaly

(2010) TR Bandgar et al.   Journal of Postgraduate Medicine

Investigation into the Efficacy and Safety of Octreotide LAR in Japanese Patients with Acromegaly: Shizuoka Study

(2009) Yutaka OKI et al.   ENDOCRINE JOURNAL

Guidelines for Acromegaly Management: An Update

(2009) S. Melmed et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly

(2009) Roberto Salvatori et al.   Pituitary

Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel® therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension

(2009) Shlomo Melmed et al.   Pituitary

Five commercially available insulin-like growth factor I (IGF-I) assays in comparison to the former Nichols Advantage IGF-I in a growth hormone treated population

(2008) Alexander Krebs et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide

(2008) N. Karavitaki et al.   CLINICAL ENDOCRINOLOGY

Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48weeks in patients with acromegaly

(2008) Philippe Chanson et al.   CLINICAL ENDOCRINOLOGY

Octreotide LARvs.surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study

(2008) Annamaria Colao et al.   CLINICAL ENDOCRINOLOGY

Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly

(2008) Annamaria Colao et al.   CLINICAL ENDOCRINOLOGY

Results of surgical and somatostatin analog therapies and their combination in acromegaly: a retrospective analysis of the German Acromegaly Register

(2008) S Petersenn et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY